Aberrant activation of AKT, the central mediator of this pathway, has been implicated in numerous malignancies including endometrial, hepatocellular and cervical cancer 26, 27, thus regulation and blockage of this kinase is an attractive approach in cancer therapy. The gene discussed is AKT1; the disease is cancer.